Dyax Corp. (NASDAQ:DYAX) was a big mover last session, as the company saw its shares rise nearly 6% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. Dyax Corp. (NASDAQ:DYAX) currently has a Zacks Rank #3 (Hold). Dyax Corp. (NASDAQ:DYAX) stock…
Trade-Ideas LLC identified Inovio Pharmaceuticals Inc (NYSEMKT:INO) as a “barbarian at the gate” (strong stocks crossing above resistance with today’s range greater than 200%) candidate. Inovio Pharmaceuticals, Inc. (NYSEMKT:INO), together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 3…
Over the past few trading days, sleepy microcap Aastrom Biosciences Inc (NASDAQ:ASTM) has exploded from $3.88 3/19/14 to a peak of $6.24 after a positive article from respected analyst Jason Napodano. Seeking Alpha’s sophisticated readership is more than capable of analyzing Aastrom Biosciences Inc (NASDAQ:ASTM)’s balance sheet. Aastrom Biosciences Inc (NASDAQ:ASTM) stock performance was -15.21%…
Illumina (NASDAQ:ILMN) SVP Nicholas Naclerio unloaded 2,000 shares of Illumina stock in a transaction that occurred on Monday, March 17th. Illumina, Inc. (NASDAQ:ILMN) stock performance was -5.42% in last session and finished the day at $152.60. Traded volume was 4,483,791 million shares in the last session and the average volume of the stock remained 1.99…
Tesaro Inc. (NASDAQ:TSRO) announced Thursday morning that it has entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration with AnaptysBio Inc. TESARO Inc. (NASDAQ:TSRO) stock performance was -5.40% in last session and finished the day at $36.76. Traded volume was 732,104.00 shares in the last session and the average volume of the stock…
Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated…
